Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that mycophenolate mofetil was effective in reducing signs and symptoms of active lichen planopilaris in 83% of patients who had failed multiple prior treatments.

This article discusses the efficacy and safety of mycophenolate mofetil and hydroxychloroquine for treating lichen planopilaris and reports no new clinical results.

This study found that low-level laser therapy may reduce inflammation and increase hair thickness in patients with lichen planopilaris after six months of treatment, though the small sample size limits the findings.

This study found that adding low-dose oral minoxidil to standard treatment for lichen planopilaris was safe but did not significantly improve hair density or thickness, although minor hair regrowth was observed in some scarring areas.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.

This study suggests that using a non-medicated, hypo-allergenic scalp clarifying shampoo may improve hair volume and reduce shedding in women with lichen planopilaris and female pattern hair loss.

This report suggests a causal connection between hyaluronic acid filler injections and the development of xanthelasma, possibly through an inflammatory reaction that increases vascular permeability and LDL leakage.

This case report suggests that identifying hyperpigmentation on the upper eyelid with specific dermoscopy patterns could help diagnose facial lichen planus pigmentosus without needing a facial biopsy.

This review discusses the potential relationship between lichen planus pigmentosus and frontal fibrosing alopecia, presenting a case study but reporting no new clinical findings.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

Men with a certain type of hair loss often use facial moisturizers, and a specific antibiotic treatment may help another hair condition.

Mycophenolic acid may help hair growth, a combination treatment improves hair thickness in male hair loss, and early treatment of frontal fibrosing alopecia is important.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study reports that Lichen planus pigmentosus is present in Moroccan patients but remains challenging to treat, with only some experiencing complete resolution of lesions after therapy.

This study reports that oral tofacitinib treatment in a patient with refractory lichen planus pigmentosus and frontal fibrosing alopecia resulted in near-complete resolution of hyperpigmentation and cessation of hairline recession over 18 months, and suggests it may be a promising therapy for these challenging conditions.

This article reports a rare case of a postmenopausal woman with coexisting lichen planus pigmentosus and classic lichen planopilaris, alongside a review of related literature.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

In this study, a network meta-analysis found that treating lichen planopilaris with a combination of clobetasol, hydroxychloroquine, and N-acetylcysteine was the most effective approach, while cyclosporine, methotrexate, and some other treatments were less effective compared to hydroxychloroquine.

In this study, methotrexate therapy with or without corticosteroids showed similar efficacy and safety in treating patients with lichen planopilaris, with no significant differences in the primary outcome or adverse effects between the two groups.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this study, researchers suggested that adipose-derived exosomes could be a promising treatment option for lichen planopilaris, particularly in cases resistant to standard therapies, by potentially aiding in symptom management and hair preservation.

This study found that platelet-rich plasma may be more effective and satisfactory than topical clobetasol for treating lichen planopilaris over six months.

This study found that applying topical 6% gabapentin twice daily reduced disease activity and scalp pruritus in a patient with lymphocytic cicatricial alopecia, with no adverse effects reported.

In this study, researchers found that among women with frontal fibrosing alopecia and hyperpigmented facial lesions, most cases were diagnosed with lichen planus pigmentosus, while some were identified as melasma or drug-induced.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This case report by the researchers observed a complete remission of lichen planopilaris in a 58-year-old woman after treatment with the JAK-1 inhibitor abrocitinib, although they noted that concurrent topical therapy might have contributed to this outcome.

This study found that both methotrexate and azathioprine were equally effective and well-tolerated in improving symptoms of lichen planopilaris over six months, with no significant difference between the two treatments in terms of efficacy.

In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.